The “attacks,” as they’re known, are debilitating and even possibly fatal. A patient with the ultra-rare genetic disease acute hepatic porphyria (AHP) is struck with excruciating abdominal pain and rushes to a doctor’s office or hospital for some type of pain relief—even a surgery—to feel better. And then another attack could come, and another, driving some patients into isolation or robbing them of their ability to work.
For the first time, a drug that might lower the frequency of these attacks is nearing FDA approval. And its developer, Alnylam Pharmaceuticals (NASDAQ: ALNY), is setting out at a major medical meeting… Read more »
UNDERWRITERS AND PARTNERS
